Investigation of serotonergic Parkinson's disease related covariance pattern using [11C] DASB/PET
We used positron emission tomography imaging with [11C] 3 amino 4 (2 dimethylaminomethylphenylsulfanyl) benzonitrile (DASB) and principal component analysis to investigate whether a specific Parkinson's disease (PD) related spatial covariance pattern could be identified for the serotonergic system. We also explored if non manifesting leucine rich repeat kinase 2 (LRRK2) mutation carriers, with normal striatal dopaminergic innervation as measured with [11C] dihydrotetrabenazine (DTBZ) exhibit a distinct spatial covariance pattern compared to healthy controls and subjects with manifest PD. 15 subjects with sporadic PD, eight subjects with LRRK2 mutation associated PD, nine LRRK2 non manifesting mutation carriers, and nine healthy controls participated in the study. The analysis was applied to the DASB non displaceable binding potential values evaluated in 42 pre defined regions of interest. PD was found to be associated with a specific spatial covariance pattern, comprising relatively decreased DASB binding in the caudate, putamen and substantia nigra and relatively preserved binding in the hypothalamus and hippocampus; the expression of this pattern in PD subjects was significantly higher than in healthy controls (P 0.001) and correlated significantly with disease duration (P 0.01) and with DTBZ binding in the more affected putamen (P 0.01) The LRRK2 non manifesting mutation carriers expressed a different pattern, also significantly different from healthy controls (P 0.001) comprising relatively decreased DASB binding in the pons, pedunculopontine nucleus, thalamus and rostral raphe nucleus, and with relatively preserved binding in the hypothalamus, amygdala, hippocampus and substantia nigra. This pattern was not present in either sporadic or LRRK2 mutation associated PD subjects. These findings, although obtained with a relatively limited number of subjects, suggest that specific and overall distinct spatial serotonergic patterns may be associated with PD and LRRK2 mutations. Alterations in regions where relative upregulation is observed in both patterns may be indicative of compensatory mechanisms preceding or protecting from disease manifestation.
NeuroImage: Clinical